Skip to main content
Premium Trial:

Request an Annual Quote

Intrexon Completes $230M Public Offering

NEW YORK (GenomeWeb) – Intrexon today said that it completed a public offering that raised $230 million in gross proceeds. 

The firm sold 5,609,756 shares of its common stock at $41 per share, which included 731,707 shares purchased by the offering's underwriters under an option granted to them by Intrexon. 

JMP Securities was the sole book-running manager while Stifel was the lead manager on the offering. Griffin Securities and Wunderlich Securities were the co-managers. 

Proceeds will be used for general corporate purposes and strategic acquisitions or investments, the Germantown, Maryland-based synthetic biology firm said when it originally announced the offering last week.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.